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Diagnosis of acute myocarditis. Myocarditis, an inflam- 
matory process infecting the myocardium, may be caused by 
bacterial, rickettsial, protozoal, fungal and almost any other 
organism. The term “secondary myocarditis” is used for 
those cases in which an etiologic agent is known, such as 
Chagas’ disease. Many cases of acute myocarditis are 
thought to be caused by viral infection. The coxsackie B 
enteroviruses and the echo virus group are known to be 
especially cardiotropic in man. Although a viral etiology for 
myocarditis may be suspected clinically, it may be difficult to 
prove. High titers of neutralizing antibody in the serum may 
suggest viral myocarditis, but they may also reflect viral 
disease elsewhere. With the exception of cytomegalovirus in 
immunocompromised hosts, viral particles have not been 
seen unequivocally in the myocardium. Typically, the pa- 
tient with myocarditis presents clinically with heart failure or 
with sudden onset of arrhythmias, both of which may be 
caused by many other cardiac conditions. Therefore, the 
clinical diagnosis of acute myocarditis is difficult, if not 
impossible, to establish. In addition, the treatment of myo- 
carditis is controversial; reports suggesting that the condi- 
tion improves with immunosuppressive agents have been 
questioned. 
The Multicenter Myocarditis Trial was established to 
examine some of these difficulties, particularly those pertain- 
ing to treatment. Patients who are entered into the trial are 
randomized to “no treatment” or to treatment with immu- 
nosuppression. If this trial is to succeed and progress is to be 
made in knowledge of the diagnosis, treatment and prognosis 
of acute myocarditis, then those patients entered into the 
trial must have an accurate diagnosis of myocarditis. The 
endomyocardial biopsy, which has achieved widespread 
acceptance and is now considered a safe procedure in 
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experienced hands (1,2), appears to be well suited for the 
definitive morphologic diagnosis of acute myocarditis. 
Role of endomyocardial biopsy in the diagnosis of acute 
myocarditis. The role of endomyocardial biopsy in acute 
myocarditis can be summarized as follows: 1) To rule out 
other diseases masquerading clinically, hemodynamically 
and electrophysiologically as acute myocarditis-a very 
important role that is often overlooked. 2) To identify the 
presence of an inflammatory infiltrate causing myocardial 
damage. 3) To investigate the effect of treatment by means of 
follow-up biopsies. 4) To monitor the progress of the patient 
after recovery and to establish the development of dilated 
cardiomyopathy, a sequence of events long suspected, but 
never proved unequivocally. However, interpretation of 
acute myocarditis by endomyocardial biopsy is difficult 
because not all lymphocytic infiltrates within the heart are 
necessarily the result of viral myocarditis. This difficulty has 
been well described and means to lessen it have been 
previously addressed (3-6). The other problem, one preva- 
lent in all biopsies including endomyocardial biopsies, is 
sampling error. 
The present study. In this issue of the Journal, Chow et 
al. (7) discuss the insensitivity of right ventricular endomy- 
ocardial biopsy in the diagnosis of myocarditis. This is not an 
original observation and has been reported previously (8- 
11). Nevertheless, I believe that their report raises an 
important issue. When read critically, it only describes ex 
vivo six hearts of patients with acute idiopathic myocarditis, 
only three of whom had heart failure. This observation must 
be put into context, because patients suspected of having 
acute myocarditis are not usually referred for biopsy until 
heart failure is present. Of the three patients in this study 
with heart failure, only two manifested a moderate infiltrate 
and one a mild infiltrate at autopsy. Although there is 
validity to the criticism of sampling error (highlighted many 
times before in previous publications), basing a study of 
sensitivity on three cases, as described in this report, ren- 
ders the results statistically dubious and gives an inaccurate 
perspective on the issue. It is misleading to introduce into 
the study secondary myocarditis and conditions such as 
fungal myocarditis, which are known to be very focal, and 
present sensitivity data based on an analysis of distribution 
of inflammatory infiltrates including these focal conditions. 
For the purpose of the Multicenter Myocarditis Trial, and 
probably in most clinical situations, patients with suspected 
myocarditis do not usually undergo biopsy until they have 
heart failure or arrhythmias. In the first place, if not in heart 
failure, this would make a difference in the sampling error 
because the disease state is often more diffuse at this stage, 
and in contracting state focal myocardial infiltrates tend to 
approximate compared with the ex vivo state. In the case of 
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severe acute myocarditis, the myocardial biopsy has greater 
accuracy because the inflammatory infiltrate is more diffuse. 
There were no cases of severe myocarditis in this study on 
which to base the sensitivity, so one is led to conclude that 
the study is biased. 
Patients for the Myocarditis Trial are entered into the trial 
and randomized only if they have positive biopsy findings, 
that is, an inflammatory infiltrate with myocyte damage as 
delineated by the Dallas criteria (7). The Dallas criteria do 
not, as erroneously indicated by Chow et al., include other 
forms of inflammatory infiltrates, such as giant cell myo- 
carditis or fungal infections. It must be emphasized that not 
only is there no clinical way of making the diagnosis of acute 
myocarditis but, in fact, there is no method for making the 
diagnosis except by a positive endomyocardial biopsy. 
Therefore the endomyocardial biopsy plays an important 
role in establishing the diagnosis for the Myocarditis Trial 
and, in some cases, ruling out other diagnoses masquerading 
as myocarditis. It is difficult to understand the purpose of 
this report with its internal inconsistency. Twice it states 
that the biopsy is necessary to make a diagnosis of myo- 
carditis and, in the final paragraph, recommends that the 
biopsy be continued in this diagnostic endeavor, yet the 
insensitivity of this technique is emphasized. 
Conclusion. Until a better technique for diagnosing acute 
myocarditis is established, it is not constructive to criticize 
the endomyocardial biopsy use on the basis of sampling 
error without at least offering an alternative solution. Impor- 
tant unresolved issues remain regarding the definitive diag- 
nosis of acute myocarditis but, in my opinion, the endomyo- 
cardial biopsy, carefully performed and intelligently 
examined (bearing in mind the obvious pitfalls), is still a 
useful diagnostic tool for the study and management of acute 
myocarditis as well as many other cardiac disease states. 
Already many new and useful facts have emerged from the 
use of the biopsy and, most likely, more will be learned from 
it. Like every other diagnostic technique, it has its limita- 
tions. These have been well documented and nothing is 
gained by reemphasizing them. In my opinion, the degree of 
insensitivity of the endomyocardial biopsy, as assessed by 
Chow et al. (7) in this issue of the Journal, is misleading, but 
their report does, at least, support the many previous studies 
advocating the procurement of as many pieces of tissue as 
possible at any one procedure to lessen the sampling error of 
endomyocardial biopsy. 
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